Skip to content

    Heranba Inds

    HERANBA
    Chemicals·27 Feb 2025
    Management Summary

    Heranba Industries reported a 7.5% YoY revenue growth to ₹1,075 crores and a 25.7% YoY PAT growth to ₹44 crores for 9M FY25. However, EBITDA margins were suppressed at 11% due to lower realizations and fixed costs from new, underutilized capacities. The company anticipates a strong recovery and growth in FY25-26, driven by new facilities commencing production and a bottoming out of pricing pressures in both domestic and export markets.

    Highlights

    5
    • Revenue from operations for 9M FY25 grew to ₹1,075 crores, up from ₹1,000 crores in 9M FY24, representing a 7.5% YoY increase.

    • Profit after tax for 9M FY25 increased to ₹44 crores, compared to ₹35 crores in 9M FY24, marking a 25.7% YoY growth.

    • Management expects a significant revenue growth of 35-40% and an EBITDA margin of 12-14% for FY25-26.

    • New facilities at Sarigam (Phase 2) and Saykha are on track to begin commercial production by the end of Q4 FY25, contributing to future growth.

    • Prices in both domestic and export markets have started to bottom out, with Q4 FY25 showing signs of revival and price improvements.

    Concerns

    4
    • EBITDA margins were suppressed at 11% for 9M FY25 due to lower realization and increased expenditures.

    • Q3 FY25 saw a significant margin drop, with gross margins down 200-300 basis points, primarily due to lower realization of technical products.

    • Fixed expenditures of approximately ₹15-20 crores from newly commenced, underutilized plant capacity in Q3 impacted profitability.

    • Challenging global macros, slowdown in demand, and higher inventory levels in the export technical business led to lower demand and price dips in Q3.

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue from Operations₹1,075 Cr+7.5%YoY
    2. 02EBITDA₹117 Cr
    3. 03EBITDA Margin11%
    4. 04Profit After Tax₹44 Cr+25.7%YoY
    5. 05Volume Growth3.5%

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹50 crores

    Debt

    Gross ₹300 crores

    Guidance & targets

    7
    CategoryTargetPriority
    Revenue
    Revenue Growth
    35% to 40%
    High
    Revenue
    Total Turnover
    ₹1,850 to ₹1,950 crores
    High
    Revenue
    H2 FY25 Revenue/Bottomline vs H1 FY25
    equal to H1 +/- 5-10%
    Medium
    Revenue
    Total Revenue
    ₹1,400 crores
    High
    Profitability
    EBITDA Margin
    12% to 14%
    High
    Profitability
    Net Profit Margin
    5% to 6%
    High
    Profitability
    EBITDA Margin
    10% to 12%
    High

    Commercial production and ramp-up of Sarigam Phase 2 and Saykha facilities

    Next quarter (Q4 FY25 results / Q1 FY26 commentary)
    CurrentExpected to commence by March end (Q4 FY25)
    TargetSuccessful commercial operations and initial ramp-up without significant slowdowns

    Why it matters

    Successful commissioning and ramp-up are crucial for achieving FY26 revenue growth targets and realizing returns on recent CAPEX investments.

    Phase 2 we expect to start by the end of Q4 FY25.

    How to verify

    capital_allocation.capex.purposes

    Risks & concerns

    4
    RiskSeverity

    Challenging global macros and demand slowdown

    The export technical business witnessed lower demand due to challenging market conditions and higher inventory, impacting revenues.Management acknowledged

    high

    Pricing pressure and lower realization

    Lower realization of products, particularly in the export market, and competition from Indian and Chinese players led to a dip in prices and suppressed gross margins.Management acknowledged

    high

    Fixed expenditures from underutilized new plant capacity

    New plant capacity commenced in October but was not properly utilized, leading to fixed expenditures of ₹15-20 crores impacting Q3 profitability.Management acknowledged

    medium

    Time-consuming new product registrations for export growth

    Expanding in markets like the US requires new product registrations, which take a longer time, potentially delaying growth from new facilities in these markets.Management acknowledged

    medium

    Q&A highlights

    6

    “Yes, Q4, we have already started seeing good demand coming in and because of demand we are also seeing price improvements in the product. No, in domestic as well as export.”

    Management confirmed that pricing pressure, particularly in export markets, was significant in Q3 but is now showing signs of bottoming out with price improvements in Q4 across both domestic and export segments.

    asked by Manish Jain

    2 min read5 chapters

    Detailed Narrative

    01

    Q3 & 9M FY25 Performance Overview

    Heranba Industries reported a 9M FY25 revenue from operations of ₹1,075 crores, marking a 7.5% increase from ₹1,000 crores in 9M FY24. Profit After Tax (PAT) for the nine-month period grew by 25.7% YoY to ₹44 crores, up from ₹35 crores in the previous year. However, EBITDA margins for 9M FY25 were suppressed at 11%, primarily due to lower product realization and increased operating expenditures.

    02

    Pricing Environment and Export Market Challenges

    The company faced significant pricing pressure, particularly in the export technical business during Q3 FY25, leading to a 200-300 basis points drop in gross margins. This was attributed to challenging global macros, a slowdown in demand, and high inventory levels. Competition from both Indian and Chinese players contributed to the price dip. Management, however, noted a slight revival in prices and demand in Q4 FY25 across both domestic and export markets, with expectations for better realization in Q1 FY26.

    03

    CAPEX and Capacity Expansion

    Heranba has deployed approximately ₹425 crores in CAPEX over the last two years, with an additional ₹50-100 crores expected to be deployed. The Sarigam Phase 2 facility and the new Greenfield Saykha facility are both anticipated to commence commercial production by the end of Q4 FY25 (March end). These new capacities are crucial for the company's projected 35-40% revenue growth in FY25-26 and a total turnover of ₹1,850-1,950 crores.

    04

    Margin Compression and Cost Headwinds

    The 9M FY25 EBITDA margin was 11%, impacted by lower realizations and increased expenditures. Specifically, Q3 FY25 saw a margin hit due to fixed costs of approximately ₹15-20 crores associated with new plant capacity that commenced in October but was not yet fully utilized. Management expects FY25 EBITDA margins to be in the range of 10-12%, with an improvement of 200-300 basis points in the next year, targeting 12-14% for FY25-26.

    05

    New Business Initiatives and Market Outlook

    The Daikaffil unit, acquired as a sick unit, started production in Q3 FY25, contributing ₹3.5 crores from contract manufacturing. The company plans to ramp up its own product manufacturing and establish an R&D setup at Daikaffil. In the US market, Heranba is a late entrant, with registrations taking time, but expects new registrations in the coming year to scale business. China currently accounts for about 10% of the total business.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.